Abstract: The present disclosure relates to an audible indicator for use with a drug delivery device comprising a resilient force member configured to reside in one of a relaxed state and a biased state. The audible indicator comprises a retainer adapted to maintain the resilient force member in the biased state. The resilient force member releases stored energy to impact a surface to generate an audible signal when the resilient force member changes from the biased state into the relaxed state.

Abstract: Provided are novel lipid nanoparticles for delivering nucleic acids such as mRNA. Also provided are methods of making and using lipid nanoparticles for delivering nucleic acids such as mRNA.

Abstract: Implementations of the present disclosure are directed to an injection device including: a reservoir including a wall defining a proximal end, a distal end and a tubular side, a plunger rod configured to be movable within the reservoir in a direction from the distal end to the proximal end, a radio frequency (RF) antenna attached to the tubular side and configured to receive an interrogation signal from an external device, and a resonating assembly configured to receive the interrogation signal from the RF antenna and to generate a modulated RF signal having a frequency associated with a position of the plunger rod.

Abstract: The present disclosure relates to a drive subassembly for a drug delivery device, the drive subassembly comprising a proximal housing part comprising a body portion and a closure portion configured as separate parts adapted to be coupled to each other, the closure portion comprising an end face and a guide rod extending from the end face in a distal direction, the guide rod adapted to be inserted into a drive spring; and a plunger, wherein the body portion comprises a profiled slot adapted to engage a plunger boss of the plunger to impede movement of the plunger in the distal direction unless the plunger is rotated to move the plunger boss out of the profiled slot. The disclosure furthermore relates to a proximal housing part for a drug delivery device, to a method for assembling the drive subassembly and to a method for assembling the drug delivery device.

Abstract: An injection device comprises an injector body having at least one indicator aperture; a medicament reservoir disposed within the injector body; a piston; and one or more status indicators. A movement of the piston expels a medicament out of the medicament reservoir, and operates to move at least one of the one or more status indicators relative to a corresponding indicator aperture.

Abstract: Needle shroud assemblies comprising a needle shroud and a support component. At least one of the needle shroud assemblies includes: a shroud body having an inner surface forming a cavity; a shroud beam arranged on the shroud body and biased radially outwards, wherein the support component is arranged on the inner surface of the shroud body and configured to form an inner radial support surface for the shroud body and/or for the shroud beam.

Abstract: An injection device includes an elongated housing extending along a longitudinal axis, a piston rod to operably engage with a piston of a cartridge filled with the medicament, a dose tracker selectively operably engageable with the piston rod, wherein the dose tracker is longitudinally displaceable relative to the housing from an initial position in a proximal direction towards at least a first activation position for setting of the dose and wherein the dose tracker is longitudinally displaceable relative to the housing in a distal direction from the at least first activation position towards the initial position for dispensing of the dose, a spring to urge the dose tracker in the proximal direction relative to the housing, an interlock to lock the dose tracker in the initial position relative to the housing, and a release member to release the interlock.

Abstract: The mixing system includes an adaptor, an integrated injection device removably attached to the adaptor comprising a switching element, a first reservoir containing a fluidic first material, and a trigger. The adaptor includes a first attachment location configured to attach a vial. The vial contains a second material within a second reservoir, wherein the second material contains a medicament formulation. The adaptor also includes a first connection element, a flow channel providing fluid communication of the switching element and the first connection element, a sensing arrangement for detecting a pre-defined position of the vial at the first attachment location, and an interlock element which is configured to allow operation of the trigger in order to establish a fluid communication between the first connection element and the first reservoir only if the sensing arrangement detects the pre-defined position of the vial at the first attachment location.

Abstract: The disclosure relates to a syringe support for supporting an axial position of a syringe relative to a housing of an autoinjector. The syringe support comprises a projecting portion, which projects from the syringe support in a distal direction and a flexible portion which axially adjoins the projecting portion. The flexible portion is adapted to axially bias the syringe in the distal direction within the housing. The disclosure further relates to an autoinjector.

Abstract: An auto-injector device comprises a stopper for expelling a medicament out of a medicament reservoir; a driving element which has a first configuration and a second configuration and is configured to change shape from the first configuration to the second configuration when the temperature of the driving element is raised above a shape change temperature, so as to drive the stopper of the syringe mechanism through the medicament reservoir; and a heating mechanism configured to actively heat the driving element. The heating mechanism is a chemical heating element configured to generate heat through an exothermic process or comprises a fluid reservoir for retaining a fluid; a heater configured to heat the fluid in the fluid reservoir; a pump configured to expel the fluid out of the fluid reservoir; and a connecting conduit arranged to carry the fluid from the fluid reservoir to the driving element.

Abstract: Systems and methods for mixing and/or reconstituting drugs are presented. A system may include an injection device, a vial, a needle, and a base station. The device has a chamber containing a first material. The vial has a chamber containing a second material. A drive unit of the base station moves the vial and/or the housing of the device relative to each other into an activated position. In the activated position, the needle is fluidly connected with the vial's chamber, and the drive unit is connected to a driver that moves the plunger in the axial direction of the device such that during fluid connection of the needle with the vial's chamber the first material is expelled from the device's chamber into the vial's chamber or the second material is expelled from the vial's chamber into the device's chamber.

Abstract: The present disclosure relates to a medicament container, configured as a flexible bag. The flexible bag includes a proximal end and a distal end having an outlet port. The flexible bag is configured to increase in length between the proximal end and the distal end when being collapsed.

Abstract: Described is a medicament delivery device (1), comprising a body (2), a container carrier (7) for retaining a medicament container within the body (2) and being slidably disposed in the body (2), a sleeve (6) slidably coupled to body (2), and a piston rod (11) coupled to the body (2) and the container carrier (7). The piston rod (11) and the container carrier (7) provide a feedback as 10 the container carrier (7) moves from a first position (P1) to a second position (P2) relative to the body (2).

Abstract: The present invention relates to amino acid sequences that are directed against interleukin 23 (IL-23). The amino acid sequences of the present invention comprise two NANOBODY® molecules against IL-23 and one NANOBODY® molecule against serum albumin, linked by two linkers. In particular, the invention relates to the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 3 (listed in Table 1 and FIG. 1) (also referred to herein as “anti-IL 23 polypeptides of the invention”).

Abstract: This disclosure relates to antigenic EBV polypeptides and their use in eliciting antibodies against EBV. Also disclosed are antigenic polypeptides comprising an EBV polypeptide and a ferritin protein.

Abstract: The present invention relates to injectors, such as pen-type injectors, that provide for administration of medicinal products from a multidose cartridge and permit a user to set a delivery dose. An injector may include a housing, a cartridge containing a medicinal product, the cartridge being retained within the housing, means for selecting a dose of the medicinal product to be expelled, and means for expelling the selected dose of the medicinal product. The housing may be a unitary housing within which the means for selecting the dose and the means for expelling the selected dose are moveably retained. Alternatively, the injector may include a housing, a piston rod, an insert located in the housing and through which the piston rod may rotate, ratchet means, a dose dial sleeve, a drive sleeve, a button located on the drive sleeve and rotatable with respect to the drive sleeve, and clutch means which upon depression of the button prevents rotation between the dose dial sleeve and the drive sleeve.

Abstract: Implementations of the present disclosure are directed to conserving energy of an injection device by using a sensor attached to the housing, the sensor configured to detect a signal associated with an amount of medicament within the injection device and to generate a sensor signal based on the signal, a control component coupled to the sensor, the control component configured to harvest energy to process the sensor signal and to generate injection device data, and an antenna coupled to the control component and configured to transmit a radio frequency signal based on the injection device data.

Abstract: The present disclosure relates to a sheath remover for removing a protective needle sheath from a drug cartridge. The sheath remover includes a resilient ring and one or more resilient legs attached to the ring and extending in a proximal direction. Each leg includes an inwardly directed ledge arranged at a proximal end of the leg. The ring consists of a resilient material allowing inward deflection of a proximal end of the ring. The present disclosure further relates to a method for assembling and a method for using the sheath remover.

Abstract: The disclosure refers to a medical device comprising a measurement unit adapted to measure a value of a physiological parameter, for example a blood glucose level, an energy storage unit providing energy supply for the measurement unit, an NFC antenna, an energy supply unit that controls the NFC antenna such that in the presence of an electromagnetic field of a pre-defined frequency range energy is withdrawn from the electromagnetic field surrounding the NFC antenna and stored in the energy storage unit, a charge control unit adapted to determine the electric charge contained in the energy storage unit, and a communication unit adapted to output a pre-defined visible, audible and/or tactile signal if the electric charge contained in the energy storage unit determined by the charge control unit is equal to or below a pre-defined minimum charge value.

Abstract: The invention relates to the novel products of formula (I): with p, q=0, 1 or 2; R1=phenyl, pyridyl; —(CH2)m—Ra; alkylene; cycloalkyl; heterocycloalkyl; alkyl; —SO2—Rb; —CO—Re; m=1 or 2; Ra=aryl, heteroaryl, —CO-cycloalkyl, —CO-heterocycloalkyl, —CO—Rb, —C(Rb)?N—ORc, —CO2Rd, —CONRxRy; Rb=alkyl, aryl, heteroaryl; Rc=H, alkyl; Rd=alkyl, cycloalkyl; Re=alkyl, cycloalkyl, aryl, heteroaryl; NRxRy with Rx,Ry=H, alkyl, cycloalkyl, alkoxy, phenyl, or form with N a ring with optionally O, N; R2, R3=H, alkyl, CF3, or form with C a ring with optionally O, S and N; R4=H, F, Cl, CH3 or CN; the morpholine is substituted with Me, and optionally substituted with F, OH; or is and the isomer of configuration R,R these products being in all the isomer forms and the salts, as medicaments, in particular as anticancer medicaments.